Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Recent patents relating to employing metabolomic data to diagnose disease states and determine the likelihood that a patient will respond to certain treatments.
Industry celebrates two newly approved genetic medicines, but patients with these blood disorders may face a long wait, and many will never access them because of their high cost.
Legal barriers are preventing generic drug makers from being able to utilize the Patent Trial and Appeal Board for its intended purpose — to serve as a faster and less cumbersome alternative to district court litigation.
Academia and the pharmaceutical industry must unite to offer more comprehensive opportunities for those wanting to stay in research in the field of drug development.